To the Editor We welcome the proposal in the Viewpoint by Tsai et al1 to focus clinical research and improve the use of radiotherapy in the care of patients with metastatic cancer through the PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program in their center. However, their assertion that stereotactic ablative body radiotherapy (SABR) provides survival benefit for patients with oligometastases does not reflect the evidence.